|Dr. Terry J. Rosen Ph.D.||Co-Founder, Chairman & CEO||296.65k||N/A||1960|
|Dr. Juan Carlos Jaen||Co-Founder, Pres & Director||351.2k||N/A||1958|
|Ms. Rekha Hemrajani M.B.A.||Chief Operating & Financial Officer||N/A||N/A||1969|
|Dr. Stephen Young Ph.D.||VP of Technology||N/A||N/A||1969|
|Ms. Katherine Bock||VP of Investor Relations & Corp. Strategy||N/A||N/A||N/A|
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial. It is also developing AB154, an anti-T-cell immunoreceptor with Ig and ITIM domains antibody, which is in Phase I trial as monotherapy; and AB680, a small-molecule inhibitor of CD73 that is in Phase I healthy volunteer study. The company has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate AB122, an anti-PD-1 antibody. Arcus Biosciences, Inc. was founded in 2015 and is headquartered in Hayward, California.
Arcus Biosciences, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 9. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 8; Compensation: 9.